InspireMD (NSPR) CEO Marvin Slosman reports 5.18% beneficial stake

Rhea-AI Filing Summary

InspireMD, Inc. executive Marvin Slosman filed a Schedule 13D reporting beneficial ownership of 2,556,760 shares of InspireMD common stock, representing 5.18% of the outstanding shares. This stake reflects his role as Chief Executive Officer and director.

The holdings include 16,722 common shares, multiple tranches of restricted stock units that are currently exercisable or become exercisable within 60 days, and 696,005 shares issuable upon exercise of stock options that are currently exercisable or become exercisable within 60 days. Only 10,330 shares were purchased for cash in a July 2025 private placement for $24,998.60; the remainder were granted as equity compensation.

Based on company information, InspireMD had 46,838,962 shares outstanding as of the date referenced. Slosman states he has no present plans for corporate actions such as mergers or control changes, and he reports no transactions in InspireMD shares in the prior 60 days, while reserving the right to buy or sell securities in the future.

Key Figures

Beneficial ownership: 2,556,760 shares Ownership percentage: 5.18% Shares outstanding: 46,838,962 shares +5 more

8 metrics

Beneficial ownership 2,556,760 shares Shares beneficially owned by Marvin Slosman

Ownership percentage 5.18% Percent of InspireMD common stock class represented

Shares outstanding 46,838,962 shares InspireMD common shares issued and outstanding as of referenced date

Private placement shares 10,330 shares Shares bought directly from issuer in July 2025

Private placement cost $24,998.60 Aggregate purchase price paid from personal funds in July 2025

Exercisable options 696,005 shares Shares issuable upon exercise of options under 2021 Equity Incentive Plan within 60 days

RSUs under 2021 plan (near-term) 1,753,522 units Restricted stock units exercisable within 60 days under 2021 Equity Incentive Plan

Excluded options (longer vesting) 241,792 shares Options vesting in more than 60 days, not included in beneficial ownership

Key Terms

Schedule 13D, restricted stock units, beneficially owned, Sole Voting Power, +2 more

6 terms

Schedule 13D regulatory

"This statement is filed by Marvin Slosman."

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

restricted stock units financial

"restricted stock units granted under the InspireMD Inc. 2021 Equity Compensation Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

beneficially owned financial

"Aggregate amount beneficially owned by each reporting person 2,556,760.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power 2,556,760.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"9 | Sole Dispositive Power 2,556,760.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

equity compensation awards financial

"all securities reported herein were acquired pursuant to equity compensation awards granted by the Issuer"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

InspireMD, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

(CUSIP Number)

Marvin Slosman
6303 Waterford District Drive, Suite 215,
Miami, FL, 33126
(888) 776-6804

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/22/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP No.

1

Name of reporting person

Marvin Slosman

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 2,556,760.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,556,760.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

2,556,760.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.18 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Consists of (i) 16,722 shares of common stock, par value $0.0001 per share (the "Shares") of InspireMD, Inc. (the "Issuer"), (ii) 12,159 restricted stock units granted outside the Issuer's equity incentive plans that are currently exercisable or exercisable within 60 days of the date hereof, (iii) 78,352 restricted stock units granted under the InspireMD, Inc. Long-Term Incentive Plan that are currently exercisable or exercisable within 60 days of the date hereof, (iv) 1,753,522 restricted stock units granted under the InspireMD Inc. 2021 Equity Compensation Plan (the "2021 Equity Incentive Plan") that are currently exercisable or exercisable within 60 days of the date hereof, and (v) 696,005 Shares issuable upon exercise of options granted under the 2021 Equity Incentive Plan that are currently exercisable or exercisable within 60 days of the date hereof. Based upon 46,838,962 Shares issued and outstanding as of the date hereof, which amount was provided to the Reporting Person by the Issuer. Does not include (i) 241,792 Shares issuable upon exercise of options granted under the 2021 Equity Incentive Plan that vest in more than 60 days of the date hereof and (ii) 1,674,903 restricted stock units granted under the 2021 Equity Incentive Plan that vest in more than 60 days of the date hereof.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: InspireMD, Inc.
(c)	Address of Issuer's Principal Executive Offices: 6303 Waterford District Drive, Suite 215, Miami, FLORIDA , 33126.
Item 2.	Identity and Background
(a)	This statement is filed by Marvin Slosman.
(b)	The principal business address of the Reporting Person is 6303 Waterford District Drive, Suite 215, Miami, Florida 33126.
(c)	The principal occupation of the Reporting Person is serving as the Chief Executive Officer and a member of the Board of Directors of the Issuer.
(d)	The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	The Reporting Person has not, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	The Reporting Person is a citizen of the United States.
Item 3.	Source and Amount of Funds or Other Consideration
	Except for 10,330 Shares acquired directly from the Issuer in a private placement in July 2025, for which the Reporting Person paid an aggregate purchase price of $24,998.60 from personal funds, all securities reported herein were acquired pursuant to equity compensation awards granted by the Issuer in connection with the Reporting Person's service as Chief Executive Officer and a member of the Board of Directors of the Issuer. Such awards were granted for no cash consideration.
Item 4.	Purpose of Transaction
	Item 3 above is hereby incorporated into this Item 4 by reference. The Reporting Person serves as an executive officer of the Issuer and, in such capacity, may be involved in reviewing transactions involving the Issuer and may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. As of the date hereof, the Reporting Person in his individual capacity does not have any present plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D. The Reporting Person may, at any time and from time to time, (i) review or reconsider his position in the Issuer or change his purpose or formulate plans or proposals with respect thereto or (ii) propose or consider one or more of the actions described in clauses (a) through (j) of Item 4 to Schedule 13D. From time to time, the Reporting Person may also acquire beneficial ownership of additional Shares or other securities of the Issuer as compensation from the Issuer, by purchase or otherwise, including, including, but not limited to, awards of restricted Shares, options to purchase Shares, and restricted stock units for Shares, or dispose of some or all of the Shares beneficially owned by the Reporting Person in the open market or in privately negotiated transactions (which may be with the Issuer or with third parties) on such terms and at such times as the Reporting Person may deem advisable.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in rows 7, 8, 9, 10, 11 and 13 on the cover pages of this Schedule 13D (including the footnotes thereto) is incorporated by reference herein.
(b)	The information contained in rows 7, 8, 9, 10, 11 and 13 on the cover pages of this Schedule 13D (including the footnotes thereto) is incorporated by reference herein.
(c)	No transactions in the Issuer's Shares were effected during the past 60 days by the Reporting Person.
(d)	Except for the Shares listed in row 9 - Sole Dispositive, persons other than the Reporting Person have the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares listed in row 10 - Shared Dispositive Power. The information set forth under Item 3 above and Item 6 of this Schedule 13D is hereby incorporated by reference.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Marvin Slosman

Signature:	/s/ Marvin Slosman
Name/Title:	Marvin Slosman
Date:	04/24/2026

FAQ

How much of InspireMD (NSPR) does CEO Marvin Slosman beneficially own?

Marvin Slosman beneficially owns 2,556,760 InspireMD shares, representing 5.18% of the common stock. This total includes common shares, restricted stock units, and options that are currently exercisable or become exercisable within 60 days of the filing date.

What makes up Marvin Slosman’s 2,556,760-share stake in InspireMD (NSPR)?

His beneficial stake includes 16,722 common shares, multiple blocks of restricted stock units, and 696,005 shares issuable upon exercise of stock options. All components are currently exercisable or become exercisable within 60 days of the statement’s date.

How many InspireMD (NSPR) shares are outstanding in this Schedule 13D?

The Schedule 13D states there were 46,838,962 shares of InspireMD common stock issued and outstanding as of the referenced date. This figure, provided by the company, is used to calculate Marvin Slosman’s reported 5.18% beneficial ownership percentage.

Did Marvin Slosman recently buy InspireMD (NSPR) shares for cash?

Yes. He acquired 10,330 shares directly from InspireMD in a July 2025 private placement, paying an aggregate $24,998.60 from personal funds. The remaining securities reported were granted as equity compensation with no cash consideration.

Has Marvin Slosman traded InspireMD (NSPR) shares in the last 60 days?

The filing states that no transactions in InspireMD shares were effected by Marvin Slosman during the 60 days before the Schedule 13D. His reported beneficial ownership reflects existing holdings and equity awards, not recent market purchases or sales.

Does Marvin Slosman have plans to change control or strategy at InspireMD (NSPR)?

According to the Schedule 13D, Slosman currently has no present plans or proposals for actions like mergers, restructurings, or other major corporate changes. However, he may review his position over time and could consider such actions in the future.